attachment
attachment
attachment
attachment
attachment
attachment
attachment
attachment

Teach me this case

analyse_media
analyse_media
analyse_media
analyse_media
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
I now have all the information needed to provide a comprehensive teaching case. Let me compile it.

📋 Teaching Case: Alcohol Withdrawal Seizure


🧑‍⚕️ Patient Summary

FieldDetails
PatientMr. S, Male, Age ~42
Admission28/6/26 - 1/7/26 (Ward MM, IP No. 1359)
Admitted forSeizure - involuntary movements of both upper and lower limbs, associated with loss of consciousness and tongue bite

1. CLINICAL PRESENTATION

Chief Complaints

  • Seizure with tonic-clonic movements (both UL + LL)
  • Loss of consciousness
  • Tongue bite

Key Social History

  • Chronic alcoholic x 10 years
  • Last drink: 2 days before admission (at night)
  • This is a classic trigger point - alcohol withdrawal seizures peak at 6-48 hours after cessation

Past History

  • Known case of: T2DM, Systemic HTN, Asthma, Epilepsy
  • Similar episode 1 year ago - admitted and treated

2. EXAMINATION FINDINGS

ParameterValueSignificance
BP120/80 mmHgNormal
PR112 bpmTachycardia - adrenergic hyperactivity of withdrawal
SpO296% on Room AirAcceptable
CNSNo focal neurological deficitSupports withdrawal etiology (not stroke/bleed)
AbdomenSoft, bowel sounds heardNo acute abdomen
Mental StatusAlert, ambulant, mood maintainedPost-ictal recovery, no delirium yet
Why tachycardia matters here: Alcohol withdrawal causes adrenergic hyperactivation (GABA suppression + NMDA upregulation). Tachycardia is an early sign of withdrawal and can progress to delirium tremens if untreated.

3. DIAGNOSIS

Provisional: Alcohol Withdrawal Seizure (AWS)

Pathophysiology - Why does this happen?

Chronic alcohol use up-regulates NMDA (excitatory) receptors and down-regulates GABA-A (inhibitory) receptors as compensatory adaptation.
When alcohol is suddenly stopped:
  • GABA inhibition drops - brain becomes hyperexcitable
  • NMDA excitatory tone is unopposed
  • Result: seizures, tremors, hallucinations, autonomic instability

Timeline of Alcohol Withdrawal Syndrome:

Time after last drinkSymptoms
6-8 hoursTremor, anxiety, diaphoresis (earliest signs)
12-24 hoursWithdrawal seizures (peak)
12-24 hoursAlcoholic hallucinosis (visual/tactile)
24-48 hoursTremulousness peaks
48-72 hours+Delirium Tremens (most dangerous)
This patient's last drink was 2 days before - seizure occurred right within the expected window.
  • ROSEN's Emergency Medicine: "Withdrawal seizures may occur 6 to 48 hours after cessation of drinking. 90% have 1-6 generalized tonic-clonic seizures."

4. INVESTIGATIONS - INTERPRETATION

CBC (28/6/26)

ValueResultInterpretation
Hb15.7 g/dLNormal
Platelets93 × 10³/µL (low)Thrombocytopenia - chronic alcohol causes bone marrow suppression + splenic sequestration
WBC4.6 × 10³/µLNormal
MCHC37.3 g/dL (raised)Can be seen with dehydration

Electrolytes

ValueResultInterpretation
Na141.2 mEq/LNormal
K3.13 mEq/L (low)Hypokalemia - alcohol causes renal K wasting; low K lowers seizure threshold
Cl106.1 mEq/LSlightly elevated

Liver Function Tests (30/6/26)

ValueResultSignificance
AST (SGOT)70 U/L (raised)Hepatocellular damage
ALT (SGPT)92 U/L (raised)Hepatocellular damage
ALP158 U/L (raised)Cholestatic component
GGT335 U/L (markedly raised)Classic marker of chronic alcohol use - GGT is the most sensitive enzyme for alcohol-related liver disease
AST:ALT ratio~0.76In alcoholic hepatitis, classically >2:1; here suggests early/mild disease
Total Bilirubin0.5 mg/dLNormal
Albumin3.9 g/dLLow-normal - nutritional depletion in alcoholism

Renal Function

  • Blood Urea: 25 mg/dL (normal)
  • Creatinine: 0.8 mg/dL (normal) - kidney function preserved

Lipase

  • 188 U/L (elevated) - suggests possible mild pancreatitis from chronic alcoholism (normal <60 U/L)

USG Abdomen

  • Grade II Fatty Liver (NAFLD/alcoholic fatty liver) - classic finding in chronic alcoholism

Urine Analysis (29/6/26)

  • Trace albumin
  • Pus cells 3-5, epithelial cells 4-6, RBC 2-4
  • Suggests mild urinary tract infection or contamination

5. TREATMENT - RATIONALE FOR EACH DRUG

Admission Medications

1. IV Fluids (NS/DNS @ 80ml/hr)
  • Chronic alcoholics are often dehydrated and malnourished
  • DNS provides glucose substrate (also protects against hypoglycemia-provoked seizures)
2. Inj. Thiamine (Vitamin B1) 200mg IV OD
  • MOST IMPORTANT drug in any alcohol-related admission
  • Alcoholics are thiamine-deficient due to poor diet + impaired absorption
  • Thiamine MUST be given BEFORE glucose to prevent precipitating Wernicke's Encephalopathy (confusion, ataxia, ophthalmoplegia)
  • IV route used for certainty of absorption
  • Maudsley Guidelines: "Parenteral thiamine is important for prophylaxis/treatment of Wernicke-Korsakoff syndrome"
3. T. Chlordiazepoxide (10 mg, 2-2-2, tapering)
  • Long-acting benzodiazepine - the gold standard for alcohol detoxification
  • Cross-tolerant with alcohol; suppresses GABA-A withdrawal hyperexcitability
  • Tapering dose prevents precipitating withdrawal from the benzodiazepine itself
  • Later switched to T. Diazepam 5mg (0-0-2) as the detox regimen was stepped down
  • Maudsley: "Chlordiazepoxide is considered to have relatively low dependence-forming potential and is the benzodiazepine used in most UK centres"
4. Inj. Lorazepam 2mg IV SOS
  • For acute breakthrough seizures
  • ROSEN's: "Lorazepam is the only benzodiazepine shown to decrease seizure recurrence and decrease need for hospitalization (NNT = 5)"
5. Inj. Levetiracetam 500mg IV BD
  • Added as a second-line anticonvulsant to prevent recurrent seizures
  • Removed on Day 4 as patient stabilized (1/7/26 notes)
  • Used because this patient had a known history of epilepsy (comorbidity)
6. Inj. Pantoprazole 40mg IV OD
  • Gastric protection - alcoholics have high risk of gastric erosions, GERD
  • Also protects against vomiting-related complications
7. Inj. Ondansetron (Emset) 8mg IV BD
  • Antiemetic - alcohol withdrawal commonly causes nausea/vomiting
  • Later changed to SOS on Day 4

6. MEDICATION CHANGES - DAY BY DAY

DayChangesReason
Day 2 (29/6)All medications continuedStable
Day 3 (30/6)Chlordiazepoxide REMOVED, Diazepam 5mg nocte started, SVP 200mg BD started, B-complex addedTransition from acute detox to maintenance; SVP for ongoing seizure prophylaxis
Day 4 (1/7)Levetiracetam REMOVED, Ondansetron moved to SOS, DischargePatient clinically stable

7. DISCHARGE MEDICATIONS (x14 days)

DrugDoseSchedulePurpose
T. Thiamine100mg1-0-1Continued supplementation to rebuild B1 stores
T. Diazepam5mg0-0-2Continued gradual detox / seizure prophylaxis at night
T. Sodium Valproate200mg2-0-2Anticonvulsant maintenance
B-Complex Tablet (BCT)-1-0-1Nutritional support (multiple B vitamins deficient in alcoholism)

8. KEY LEARNING POINTS

  1. Alcohol withdrawal seizures = 6-48h after last drink - this patient fits perfectly (2 days = ~48h)
  2. Tachycardia at admission (PR 112) = adrenergic hyperactivity, a red flag for impending severe withdrawal
  3. Hypokalemia (K 3.13) lowers seizure threshold - must be corrected
  4. GGT is the most sensitive marker for chronic alcohol use (this patient: 335 U/L)
  5. Thrombocytopenia - characteristic of chronic alcoholism (direct bone marrow suppression + hypersplenism)
  6. Thiamine BEFORE glucose - the cardinal rule; skipping it can precipitate Wernicke's encephalopathy
  7. Benzodiazepines are first-line for AWS - chlordiazepoxide preferred for detox (long-acting, low abuse potential); lorazepam for acute seizure control
  8. Wernicke-Korsakoff spectrum - always consider in chronic alcoholics presenting with any neurological symptom
  9. Grade II fatty liver on USG - confirms chronic alcohol-related hepatic injury
  10. Elevated lipase (188 U/L) - watch for alcoholic pancreatitis

9. WHAT COULD HAVE BEEN DONE ADDITIONALLY?

  • CIWA-Ar scale (Clinical Institute Withdrawal Assessment for Alcohol) should be scored to guide BZD dosing (score >15 = severe withdrawal)
  • Blood alcohol level on admission
  • Head CT to rule out intracerebral bleed (especially given tongue bite and LOC)
  • Serum magnesium - commonly depleted in alcoholics, causes refractory hypokalemia
  • Formal addiction counseling / referral at discharge

Sources: ROSEN's Emergency Medicine; Goldman-Cecil Medicine; Maudsley Prescribing Guidelines in Psychiatry, 15th ed.

Tell me intervention

Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
I have enough textbook evidence. Here is the complete pharmacist intervention write-up for this case:

💊 Pharmacist Interventions - Mr. S (Alcohol Withdrawal Seizure)

A clinical pharmacist reviews this case using the Drug Therapy Problem (DTP) framework: identifying issues of unnecessary drug use, need for additional therapy, wrong drug, dose too high/low, adverse drug reaction, or non-adherence.

INTERVENTION 1 - Thiamine Given IV Before Glucose ✅ (Appropriate, Reinforce)

Observation: Inj. Thiamine 200mg IV was prescribed alongside DNS (dextrose-containing fluid).
DTP: Potential Adverse Drug Reaction (if order was reversed)
Pharmacist Role:
  • Verify and confirm that Thiamine is administered BEFORE or simultaneously with DNS - never after glucose alone.
  • Glucose given to a thiamine-deficient patient consumes the last reserves of thiamine and can precipitate Wernicke's Encephalopathy (WE).
Maudsley Prescribing Guidelines: "As thiamine is required to utilise glucose, a glucose load in a thiamine-deficient patient can precipitate Wernicke's encephalopathy."
Classic Triad of WE to monitor for:
  • Ophthalmoplegia / nystagmus
  • Ataxia
  • Confusion / altered consciousness
Intervention: Counsel nursing staff - Thiamine first, then glucose. Document the sequence in the MAR sheet.
Discharge dose (100mg 1-0-1 x14 days) is appropriate for rebuilding thiamine stores. Counsel patient on oral thiamine adherence after discharge.

INTERVENTION 2 - Hypokalemia Not Treated ⚠️ (Drug Needed - Untreated Indication)

Observation: Potassium = 3.13 mEq/L (low; normal 3.5-5.0 mEq/L). No potassium supplementation was prescribed at admission.
DTP: Needs Additional Drug Therapy
Why it matters:
  • Hypokalemia lowers the seizure threshold - directly worsens the presenting complaint
  • Chronic alcohol use causes renal potassium wasting and poor dietary intake
  • Hypokalemia also causes cardiac arrhythmias (this patient already had tachycardia PR 112)
Intervention: Recommend to the treating physician:
  • Inj./T. Potassium Chloride (KCl) supplementation - IV if K <3.0, oral if K 3.0-3.5
  • Recheck serum K after 24-48h to confirm correction
  • Also check serum Magnesium - hypomagnesemia is common in alcoholism and causes refractory hypokalemia (Mg must be corrected first for K to be retained)

INTERVENTION 3 - GGT Markedly Elevated + Elevated Lipase (Monitor / Counsel) ⚠️

Observation:
  • GGT = 335 U/L (very high - classic marker of chronic alcohol use)
  • Lipase = 188 U/L (elevated, suggests early/subclinical pancreatitis)
  • USG: Grade II Fatty Liver
DTP: Adverse Drug Reaction (alcohol-induced organ damage) + Need for Monitoring
Intervention:
  • Inform physician about elevated lipase - consider clinical correlation for acute alcoholic pancreatitis (abdominal pain, nausea, vomiting were present at admission)
  • Monitor LFTs, lipase trend - repeat at follow-up
  • Counsel patient: Continued alcohol use risks progression from fatty liver → alcoholic hepatitis → cirrhosis
  • Advise: absolutely no alcohol; referral to de-addiction services

INTERVENTION 4 - Chlordiazepoxide Tapering (Dose Monitoring) ✅

Observation: T. Chlordiazepoxide 10mg prescribed at 2-2-2 (Day 1 only) and then stopped on Day 3 (replaced by Diazepam 5mg nocte).
DTP: Review dose/tapering schedule adequacy
Pharmacist Role:
  • Chlordiazepoxide is the drug of choice for alcohol detoxification - it is long-acting, has active metabolites, and has low abuse potential
  • The tapering here appears brief (1 day only at 30mg/day total)
  • Verify using CIWA-Ar score - if score >15, higher starting doses are needed; if <10, oral BZD may not be needed at all
  • Monitor for over-sedation (risk is higher with liver disease present)
Maudsley: "A general rule of thumb is that the starting dose can be estimated from current alcohol consumption. If 20 units/day: start 20mg QID, then taper."
Intervention: Recommend CIWA-Ar scoring at each shift to guide BZD dosing rather than fixed low dose. Document the taper schedule clearly.

INTERVENTION 5 - Levetiracetam Use (Rational Review) ⚠️

Observation: Inj. Levetiracetam 500mg BD was started at admission but removed on Day 4.
DTP: Possibly Unnecessary Drug Therapy (or appropriate add-on given comorbid epilepsy)
Discussion:
  • Levetiracetam is not the standard drug for alcohol withdrawal seizures - benzodiazepines are first-line
  • However, this patient has a known history of epilepsy - so levetiracetam may have been added to provide broad-spectrum seizure cover beyond alcohol withdrawal
  • Sodium Valproate was continued at discharge for this reason (dual purpose: epilepsy + mood stabilizer effect)
Pharmacist Intervention:
  • Clarify with physician: is the ongoing epilepsy diagnosis separate from the withdrawal seizures?
  • If yes: sodium valproate at discharge (200mg 2-0-2 x14 days) is appropriate, but long-term epilepsy management plan should be formalized
  • If no: levetiracetam removal on Day 4 is appropriate as withdrawal period is past

INTERVENTION 6 - Pantoprazole: Indication Review (Appropriate) ✅

Observation: Inj. Pantoprazole 40mg IV OD on admission.
DTP: Review necessity / route
  • Appropriate - alcohol causes gastric mucosal erosions, GERD, and risk of GI bleed (especially with thrombocytopenia)
  • Step-down to oral pantoprazole should have been made by Day 2-3 once patient is tolerating orals
  • Not included in discharge prescription - verify if intentional (short course) or an omission
Intervention: Counsel patient on alcohol-related gastric injury. If symptomatic (epigastric pain), continue oral PPI at home.

INTERVENTION 7 - Discharge Counseling (Patient Education) 📋

Key counseling points the pharmacist must deliver:
TopicMessage
ThiamineTake every day morning and night - protects your brain and nerves
DiazepamOnly at night as prescribed - do not take extra doses; do not mix with alcohol
Sodium ValproateFor seizure prevention - do not stop suddenly; take with food to reduce nausea
B-ComplexReplace vitamins lost due to alcohol
Alcohol abstinenceEven one drink can restart the withdrawal cycle and trigger seizures
Follow-upRepeat LFTs, lipase, serum K in 2 weeks
Warning signsReturn immediately if: confusion, shaking, hallucinations, abdominal pain worsen
De-addictionRefer to psychiatrist / de-addiction center for structured support

Summary of All DTPs

#DTP TypeProblemPharmacist Action
1ADR preventionThiamine-glucose sequencingConfirm order; educate nurses
2Needs additional therapyHypokalemia untreatedRecommend KCl + Mg supplementation
3ADR / MonitoringElevated lipase + GGTAlert physician; monitor; counsel on alcohol
4Dosing problemCIWA-Ar not scored; BZD taper briefRecommend CIWA-Ar guided dosing
5Unnecessary drug / clarificationLevetiracetam role unclearClarify epilepsy vs. AWS seizure; formalize epilepsy plan
6Inappropriate route / omissionIV PPI not stepped down; not on discharge RxStep down to oral; assess if needed at discharge
7Non-adherence riskHigh risk of relapseComprehensive discharge counseling + referral

Sources: Maudsley Prescribing Guidelines in Psychiatry, 15th ed.; ROSEN's Emergency Medicine; Goldman-Cecil Medicine

Generate a teaching presentation on alcohol withdrawal management

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Running Command

ls /home/daytona/workspace/ 2>/dev/null || echo "workspace empty or doesn't exis…

Running Command

mkdir -p /home/daytona/workspace/aws-presentation && echo "created"

Writing File

~/aws-presentation/build.js

const pptxgen = require("pptxgenjs");
const pres = new pptxgen();
pres.layout = "LAYOUT_16x9";
pres.title = "Alcohol Withdrawal Management";
pres.author = "Clinical Pharmacology Teaching";

// ── COLOUR PALETTE ──────────────────────────────────────────────
const NAVY   = "0D1B2A";   // dominant background
const TEAL   = "1B7F79";   // accent bars / section headers
const AMBER  = "E8A838";   // highlight / key facts
const WHITE  = "FFFFFF";
const LGRAY  = "E8EDF2";   // card fill
const DGRAY  = "2C3E50";   // body text on light bg
const RED    = "C0392B";   // danger / warning
const GREEN  = "1E8449";   // safe / mild

// ── HELPERS ─────────────────────────────────────────────────────
function addBg(slide, color) {
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: 10, h: 5.625, fill: { color } });
}

function addAccentBar(slide, color = TEAL) {
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: 10, h: 0.08, fill: { color } });
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 5.545, w: 10, h: 0.08, fill: { color } });
}

function sectionTitle(slide, text, sub) {
  addBg(slide, NAVY);
  // centre accent line
  slide.addShape(pres.shapes.RECTANGLE, { x: 3.5, y: 2.65, w: 3, h: 0.06, fill: { color: AMBER } });
  slide.addText(text, {
    x: 0.5, y: 1.9, w: 9, h: 1,
    fontSize: 40, bold: true, color: WHITE, align: "center", fontFace: "Calibri"
  });
  if (sub) slide.addText(sub, {
    x: 1, y: 2.9, w: 8, h: 0.6,
    fontSize: 18, color: TEAL, align: "center", fontFace: "Calibri", italic: true
  });
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 1 — TITLE
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  const s = pres.addSlide();
  addBg(s, NAVY);
  // bold teal sidebar
  s.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: 0.18, h: 5.625, fill: { color: TEAL } });
  // amber accent
  s.addShape(pres.shapes.RECTANGLE, { x: 0.5, y: 3.5, w: 5.5, h: 0.07, fill: { color: AMBER } });

  s.addText("ALCOHOL WITHDRAWAL", {
    x: 0.5, y: 0.8, w: 9, h: 1,
    fontSize: 44, bold: true, color: WHITE, fontFace: "Calibri", charSpacing: 2
  });
  s.addText("MANAGEMENT", {
    x: 0.5, y: 1.75, w: 9, h: 0.9,
    fontSize: 44, bold: true, color: AMBER, fontFace: "Calibri", charSpacing: 2
  });
  s.addText("A Comprehensive Clinical Teaching Module", {
    x: 0.5, y: 2.85, w: 8, h: 0.55,
    fontSize: 17, color: LGRAY, fontFace: "Calibri", italic: true
  });
  s.addText([
    { text: "Pathophysiology  •  ", options: {} },
    { text: "CIWA-Ar Assessment  •  ", options: {} },
    { text: "Pharmacotherapy  •  ", options: {} },
    { text: "Complications  •  ", options: {} },
    { text: "Pharmacist Role", options: {} }
  ], {
    x: 0.5, y: 3.75, w: 9, h: 0.5,
    fontSize: 12, color: "8ABFD4", fontFace: "Calibri"
  });
  s.addText("Maudsley Prescribing Guidelines, 15e  |  ROSEN's Emergency Medicine  |  Goldman-Cecil Medicine", {
    x: 0.5, y: 5.2, w: 9, h: 0.3,
    fontSize: 9, color: "5A7A8A", fontFace: "Calibri"
  });
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 2 — OVERVIEW / AGENDA
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  const s = pres.addSlide();
  addBg(s, LGRAY);
  addAccentBar(s);

  s.addText("What We Will Cover", {
    x: 0.5, y: 0.15, w: 9, h: 0.55,
    fontSize: 26, bold: true, color: NAVY, fontFace: "Calibri"
  });

  const topics = [
    ["01", "Epidemiology & Overview",       "Who gets AWS and why it matters"],
    ["02", "Pathophysiology",               "GABA / NMDA imbalance explained"],
    ["03", "Clinical Features & Timeline",  "What you will see and when"],
    ["04", "CIWA-Ar Scoring",               "Quantifying severity objectively"],
    ["05", "Pharmacotherapy",               "Benzodiazepines, thiamine, adjuncts"],
    ["06", "Delirium Tremens",              "The most dangerous complication"],
    ["07", "Wernicke-Korsakoff",            "Thiamine deficiency spectrum"],
    ["08", "Drug Therapy Problems",         "Pharmacist interventions"],
    ["09", "Discharge & Counseling",        "Preventing relapse & complications"],
  ];

  const cols = [[0], [1,2,3,4], [5,6,7,8]];
  const positions = [
    { x: 0.3, y: 0.85 },
    { x: 0.3, y: 0.85 },
    { x: 3.5, y: 0.85 },
    { x: 6.7, y: 0.85 },
  ];

  let col = 0;
  const xStarts = [0.3, 3.45, 6.6];
  const yStart = 0.85;
  topics.forEach((t, i) => {
    const c = i < 3 ? 0 : i < 6 ? 1 : 2;
    const row = i % 3;
    const x = xStarts[c];
    const y = yStart + row * 1.45;

    s.addShape(pres.shapes.RECTANGLE, {
      x, y, w: 3.0, h: 1.3,
      fill: { color: WHITE },
      shadow: { type: "outer", color: "AAAAAA", blur: 5, offset: 2, angle: 135, opacity: 0.18 }
    });
    s.addShape(pres.shapes.RECTANGLE, { x, y, w: 0.55, h: 1.3, fill: { color: TEAL } });
    s.addText(t[0], {
      x, y: y + 0.38, w: 0.55, h: 0.55,
      fontSize: 16, bold: true, color: WHITE, align: "center", fontFace: "Calibri"
    });
    s.addText(t[1], {
      x: x + 0.62, y: y + 0.12, w: 2.3, h: 0.5,
      fontSize: 11, bold: true, color: NAVY, fontFace: "Calibri"
    });
    s.addText(t[2], {
      x: x + 0.62, y: y + 0.6, w: 2.3, h: 0.55,
      fontSize: 9.5, color: "556070", fontFace: "Calibri", italic: true
    });
  });
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 3 — SECTION DIVIDER: PATHOPHYSIOLOGY
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  const s = pres.addSlide();
  sectionTitle(s, "PATHOPHYSIOLOGY", "Why does alcohol withdrawal cause seizures?");
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 4 — GABA/NMDA MECHANISM
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  const s = pres.addSlide();
  addBg(s, WHITE);
  s.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: 10, h: 0.55, fill: { color: NAVY } });
  s.addText("Mechanism of Alcohol Withdrawal", {
    x: 0.3, y: 0.05, w: 9.4, h: 0.45,
    fontSize: 20, bold: true, color: WHITE, fontFace: "Calibri"
  });

  // Three state boxes
  const states = [
    {
      title: "CHRONIC ALCOHOL USE",
      color: "1A5276",
      items: [
        "↑ GABA-A receptor activity (inhibition)",
        "Alcohol potentiates GABA → brain adapts",
        "Down-regulates GABA-A receptors",
        "↓ NMDA receptor sensitivity (excitation suppressed)",
        "Brain compensates: UP-regulates NMDA receptors",
      ]
    },
    {
      title: "ABRUPT CESSATION",
      color: RED,
      items: [
        "GABA inhibition suddenly drops",
        "Down-regulated GABA-A can't compensate",
        "NMDA excitatory receptors now unmasked",
        "Net result: BRAIN HYPEREXCITABILITY",
        "Unopposed sympathetic drive",
      ]
    },
    {
      title: "CLINICAL RESULT",
      color: TEAL,
      items: [
        "Tremors (earliest — 6-8h)",
        "Seizures (peak 12-24h)",
        "Hallucinations (12-36h)",
        "Autonomic instability",
        "Delirium Tremens (48-72h+)",
      ]
    }
  ];

  states.forEach((st, i) => {
    const x = 0.18 + i * 3.28;
    s.addShape(pres.shapes.RECTANGLE, { x, y: 0.7, w: 3.1, h: 0.42, fill: { color: st.color } });
    s.addText(st.title, {
      x, y: 0.72, w: 3.1, h: 0.38,
      fontSize: 11, bold: true, color: WHITE, align: "center", fontFace: "Calibri"
    });
    st.items.forEach((item, j) => {
      s.addText([
        { text: "▸  ", options: { color: st.color, bold: true } },
        { text: item, options: { color: DGRAY } }
      ], {
        x: x + 0.1, y: 1.2 + j * 0.75, w: 2.95, h: 0.65,
        fontSize: 11, fontFace: "Calibri"
      });
    });
    // Arrow between boxes
    if (i < 2) {
      s.addText("→", {
        x: x + 3.08, y: 1.5, w: 0.25, h: 0.5,
        fontSize: 22, bold: true, color: AMBER, align: "center"
      });
    }
  });

  s.addShape(pres.shapes.RECTANGLE, { x: 0.18, y: 5.15, w: 9.64, h: 0.35, fill: { color: LGRAY } });
  s.addText("Key principle: Benzodiazepines restore GABA-ergic tone → suppress the hyperexcitable state", {
    x: 0.3, y: 5.18, w: 9.4, h: 0.28,
    fontSize: 10.5, italic: true, color: NAVY, fontFace: "Calibri"
  });
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 5 — CLINICAL TIMELINE
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  const s = pres.addSlide();
  addBg(s, NAVY);
  s.addText("Clinical Timeline of Alcohol Withdrawal", {
    x: 0.4, y: 0.12, w: 9.2, h: 0.52,
    fontSize: 22, bold: true, color: WHITE, fontFace: "Calibri"
  });
  s.addShape(pres.shapes.RECTANGLE, { x: 0.4, y: 0.66, w: 9.2, h: 0.05, fill: { color: AMBER } });

  // Timeline axis
  s.addShape(pres.shapes.RECTANGLE, { x: 0.5, y: 3.1, w: 9, h: 0.06, fill: { color: AMBER } });
  s.addText("LAST DRINK →", { x: 0.5, y: 3.22, w: 2, h: 0.3, fontSize: 9, color: AMBER, fontFace: "Calibri" });
  s.addText("TIME", { x: 8.5, y: 3.22, w: 1, h: 0.3, fontSize: 9, color: AMBER, fontFace: "Calibri" });

  const events = [
    { h: "6-8h",   label: "Tremor\nAnxiety\nDiaphoresis", x: 1.0,  color: GREEN,  danger: false },
    { h: "12-24h", label: "SEIZURES\n(Tonic-Clonic)\nPeak risk", x: 3.0, color: AMBER,  danger: true  },
    { h: "12-36h", label: "Hallucinations\n(Visual/Auditory)", x: 5.1, color: "E67E22", danger: false },
    { h: "48-72h+",label: "DELIRIUM\nTREMENS", x: 7.2,  color: RED,    danger: true  },
  ];

  events.forEach(ev => {
    // pole
    s.addShape(pres.shapes.RECTANGLE, { x: ev.x + 0.55, y: 1.0, w: 0.05, h: 2.1, fill: { color: ev.color } });
    // top flag
    s.addShape(pres.shapes.RECTANGLE, {
      x: ev.x, y: ev.danger ? 0.75 : 0.75, w: 1.2, h: 1.0,
      fill: { color: ev.color }, shadow: { type: "outer", color: "000000", blur: 4, offset: 2, angle: 135, opacity: 0.25 }
    });
    s.addText(ev.h, {
      x: ev.x + 0.03, y: 0.78, w: 1.14, h: 0.26,
      fontSize: 10, bold: true, color: WHITE, align: "center", fontFace: "Calibri"
    });
    s.addText(ev.label, {
      x: ev.x + 0.03, y: 1.04, w: 1.14, h: 0.66,
      fontSize: 8.5, color: WHITE, align: "center", fontFace: "Calibri"
    });
    // dot on axis
    s.addShape(pres.shapes.OVAL, {
      x: ev.x + 0.48, y: 3.03, w: 0.19, h: 0.19, fill: { color: ev.color }
    });
  });

  // Bottom key facts
  const facts = [
    "90% of patients have 1-6 GTC seizures",
    "60% of seizures cluster within 6 hours",
    "~30% of AWS patients progress to delirium tremens",
    "Delirium tremens mortality: 1-5% (untreated: up to 15%)",
  ];
  facts.forEach((f, i) => {
    s.addText([
      { text: "◆  ", options: { color: AMBER, bold: true } },
      { text: f, options: { color: WHITE } }
    ], {
      x: 0.5 + (i % 2) * 4.7,
      y: 3.6 + Math.floor(i / 2) * 0.5,
      w: 4.5, h: 0.42,
      fontSize: 11, fontFace: "Calibri"
    });
  });
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 6 — CIWA-Ar SCORING
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  const s = pres.addSlide();
  addBg(s, WHITE);
  s.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: 10, h: 0.55, fill: { color: TEAL } });
  s.addText("CIWA-Ar: Clinical Institute Withdrawal Assessment for Alcohol (Revised)", {
    x: 0.3, y: 0.05, w: 9.4, h: 0.45,
    fontSize: 16, bold: true, color: WHITE, fontFace: "Calibri"
  });

  // Left: 10 items
  s.addText("10 Assessed Parameters", {
    x: 0.3, y: 0.65, w: 4.5, h: 0.38,
    fontSize: 14, bold: true, color: NAVY, fontFace: "Calibri"
  });

  const items = [
    "1. Nausea / Vomiting",
    "2. Tremor",
    "3. Paroxysmal Sweats",
    "4. Anxiety",
    "5. Agitation",
    "6. Tactile Disturbances",
    "7. Auditory Disturbances",
    "8. Visual Disturbances",
    "9. Headache / Fullness in Head",
    "10. Orientation / Clouding of Sensorium",
  ];
  items.forEach((item, i) => {
    s.addText(item, {
      x: 0.3, y: 1.1 + i * 0.41,
      w: 4.4, h: 0.37,
      fontSize: 11, color: DGRAY, fontFace: "Calibri",
      bullet: { type: "number" }
    });
  });

  // Right: severity table
  s.addText("Severity & Action", {
    x: 5.2, y: 0.65, w: 4.5, h: 0.38,
    fontSize: 14, bold: true, color: NAVY, fontFace: "Calibri"
  });

  const rows = [
    { score: "≤ 8",    sev: "Mild",     action: "Monitor; no BZD needed",                  col: GREEN },
    { score: "9-14",   sev: "Moderate", action: "Symptomatic BZD; close monitoring",         col: AMBER },
    { score: "15-19",  sev: "Severe",   action: "Chlordiazepoxide taper; hospitalise",       col: "E67E22" },
    { score: "≥ 20",   sev: "Critical", action: "IV BZD; consider ICU; monitor DT risk",     col: RED },
  ];
  rows.forEach((r, i) => {
    const y = 1.12 + i * 1.02;
    s.addShape(pres.shapes.RECTANGLE, { x: 5.15, y, w: 4.6, h: 0.92, fill: { color: LGRAY } });
    s.addShape(pres.shapes.RECTANGLE, { x: 5.15, y, w: 0.85, h: 0.92, fill: { color: r.col } });
    s.addText(r.score, { x: 5.15, y: y + 0.14, w: 0.85, h: 0.6, fontSize: 14, bold: true, color: WHITE, align: "center", fontFace: "Calibri" });
    s.addText(r.sev, { x: 6.08, y: y + 0.06, w: 3.6, h: 0.34, fontSize: 12, bold: true, color: DGRAY, fontFace: "Calibri" });
    s.addText(r.action, { x: 6.08, y: y + 0.44, w: 3.6, h: 0.38, fontSize: 9.5, color: "55667A", fontFace: "Calibri" });
  });

  s.addText("Max score = 67  |  Each item scored 0-7  |  Complete in ~5 minutes  |  Score every 4-8h during detox", {
    x: 0.3, y: 5.25, w: 9.4, h: 0.3,
    fontSize: 9.5, color: TEAL, italic: true, fontFace: "Calibri"
  });
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 7 — SECTION DIVIDER: PHARMACOTHERAPY
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  const s = pres.addSlide();
  sectionTitle(s, "PHARMACOTHERAPY", "Benzodiazepines, Thiamine & Adjuncts");
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 8 — BENZODIAZEPINES (First-Line)
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  const s = pres.addSlide();
  addBg(s, WHITE);
  s.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: 10, h: 0.55, fill: { color: NAVY } });
  s.addText("Benzodiazepines — First-Line Treatment for AWS", {
    x: 0.3, y: 0.07, w: 9.4, h: 0.42,
    fontSize: 18, bold: true, color: WHITE, fontFace: "Calibri"
  });

  // Why BZDs?
  s.addShape(pres.shapes.RECTANGLE, { x: 0.25, y: 0.65, w: 9.5, h: 0.34, fill: { color: LGRAY } });
  s.addText("Why Benzodiazepines? Cross-tolerance with alcohol → restore GABA-A inhibition → suppress neuronal hyperexcitability & raise seizure threshold", {
    x: 0.35, y: 0.67, w: 9.3, h: 0.3, fontSize: 10.5, color: DGRAY, italic: true, fontFace: "Calibri"
  });

  const drugs = [
    {
      name: "Chlordiazepoxide",
      type: "Long-acting (gold standard for detox)",
      dose: "Starting dose = alcohol units/day (mg QID)\ne.g. 20 units → 20mg QID, then taper over 5-7 days",
      pros: ["Low dependence potential", "Self-tapering via active metabolites", "Preferred in most centres (NICE)"],
      cons: ["Avoid in liver failure (use oxazepam/lorazepam)", "Long half-life risk in elderly"],
      color: TEAL,
    },
    {
      name: "Diazepam",
      type: "Long-acting (used for acute seizures / step-down)",
      dose: "5-10mg orally TID-QID, tapering\nIV 5-10mg for acute seizure control",
      pros: ["Rapid onset IV", "Effective for acute control", "Step-down from chlordiazepoxide"],
      cons: ["Higher abuse potential", "Accumulates in liver disease"],
      color: "1A5276",
    },
    {
      name: "Lorazepam",
      type: "Short-acting (acute seizure use only)",
      dose: "IV 2mg SOS for active seizure\nRepeat q5-10min if needed",
      pros: ["Only BZD proven to ↓ seizure recurrence (NNT=5)", "Safe in liver disease", "Predictable IM absorption"],
      cons: ["Does not self-taper", "Not suitable for full detox course"],
      color: AMBER,
    },
  ];

  drugs.forEach((d, i) => {
    const x = 0.22 + i * 3.26;
    s.addShape(pres.shapes.RECTANGLE, { x, y: 1.1, w: 3.1, h: 4.35, fill: { color: LGRAY } });
    s.addShape(pres.shapes.RECTANGLE, { x, y: 1.1, w: 3.1, h: 0.52, fill: { color: d.color } });
    s.addText(d.name, { x: x + 0.1, y: 1.13, w: 2.9, h: 0.28, fontSize: 12, bold: true, color: WHITE, fontFace: "Calibri" });
    s.addText(d.type, { x: x + 0.1, y: 1.38, w: 2.9, h: 0.22, fontSize: 8.5, color: WHITE, fontFace: "Calibri", italic: true });

    s.addText("DOSE:", { x: x + 0.1, y: 1.72, w: 0.6, h: 0.22, fontSize: 9, bold: true, color: d.color, fontFace: "Calibri" });
    s.addText(d.dose, { x: x + 0.1, y: 1.93, w: 2.9, h: 0.7, fontSize: 9, color: DGRAY, fontFace: "Calibri" });

    s.addText("✓ Advantages:", { x: x + 0.1, y: 2.72, w: 2.9, h: 0.25, fontSize: 9.5, bold: true, color: GREEN, fontFace: "Calibri" });
    d.pros.forEach((p, j) => {
      s.addText("• " + p, { x: x + 0.1, y: 2.98 + j * 0.3, w: 2.9, h: 0.28, fontSize: 8.5, color: DGRAY, fontFace: "Calibri" });
    });

    s.addText("⚠ Cautions:", { x: x + 0.1, y: 3.95, w: 2.9, h: 0.25, fontSize: 9.5, bold: true, color: RED, fontFace: "Calibri" });
    d.cons.forEach((c, j) => {
      s.addText("• " + c, { x: x + 0.1, y: 4.2 + j * 0.3, w: 2.9, h: 0.28, fontSize: 8.5, color: DGRAY, fontFace: "Calibri" });
    });
  });
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 9 — THIAMINE & ADJUNCT THERAPY
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  const s = pres.addSlide();
  addBg(s, WHITE);
  s.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: 10, h: 0.55, fill: { color: TEAL } });
  s.addText("Thiamine & Adjunct Pharmacotherapy", {
    x: 0.3, y: 0.08, w: 9.4, h: 0.42,
    fontSize: 20, bold: true, color: WHITE, fontFace: "Calibri"
  });

  // THIAMINE BOX (big)
  s.addShape(pres.shapes.RECTANGLE, { x: 0.25, y: 0.68, w: 5.8, h: 3.0, fill: { color: LGRAY } });
  s.addShape(pres.shapes.RECTANGLE, { x: 0.25, y: 0.68, w: 5.8, h: 0.45, fill: { color: "8B4513" } });
  s.addText("⭐ THIAMINE (Vitamin B1) — MANDATORY IN ALL CASES", {
    x: 0.35, y: 0.71, w: 5.6, h: 0.38,
    fontSize: 11, bold: true, color: WHITE, fontFace: "Calibri"
  });

  const thi = [
    ["Why?", "Alcoholics are thiamine-deficient: poor diet + impaired GI absorption + hepatic storage depletion"],
    ["Critical rule:", "Give thiamine BEFORE or WITH glucose/dextrose — glucose load in deficient patient precipitates Wernicke's Encephalopathy"],
    ["Inpatient dose:", "100-200mg IV/IM OD (Pabrinex or thiamine injection); 200mg IV used in this case"],
    ["Discharge:", "100mg oral BD x 14 days minimum; longer if malnourished"],
    ["Prevents:", "Wernicke's Encephalopathy → Korsakoff Syndrome (irreversible amnesia)"],
  ];
  thi.forEach((row, i) => {
    s.addText(row[0], {
      x: 0.35, y: 1.2 + i * 0.47, w: 1.1, h: 0.38,
      fontSize: 9.5, bold: true, color: "8B4513", fontFace: "Calibri"
    });
    s.addText(row[1], {
      x: 1.5, y: 1.2 + i * 0.47, w: 4.4, h: 0.38,
      fontSize: 9.5, color: DGRAY, fontFace: "Calibri"
    });
  });

  // Right column: adjuncts
  const adjuncts = [
    {
      drug: "Sodium Valproate",
      use: "Seizure prophylaxis (esp. if pre-existing epilepsy)",
      dose: "200mg BD-TID",
      note: "Not first-line for AWS alone but useful for comorbid epilepsy"
    },
    {
      drug: "Levetiracetam",
      use: "Add-on anticonvulsant in complex cases",
      dose: "500mg IV/oral BD",
      note: "Used when seizure risk is high; taper once withdrawal phase passes"
    },
    {
      drug: "Pantoprazole",
      use: "Gastric protection (alcohol erosions, GERD)",
      dose: "40mg IV/oral OD",
      note: "Step down to oral once tolerating food"
    },
    {
      drug: "B-Complex",
      use: "Replenish B2, B6, B12, folate — all depleted",
      dose: "1-0-1 orally",
      note: "Continue for weeks; supports neurological recovery"
    },
  ];

  adjuncts.forEach((a, i) => {
    const y = 0.68 + i * 1.15;
    s.addShape(pres.shapes.RECTANGLE, { x: 6.25, y, w: 3.5, h: 1.05, fill: { color: LGRAY } });
    s.addShape(pres.shapes.RECTANGLE, { x: 6.25, y, w: 0.1, h: 1.05, fill: { color: TEAL } });
    s.addText(a.drug, { x: 6.42, y: y + 0.04, w: 3.2, h: 0.3, fontSize: 11, bold: true, color: NAVY, fontFace: "Calibri" });
    s.addText(a.use + " — " + a.dose, { x: 6.42, y: y + 0.33, w: 3.2, h: 0.3, fontSize: 9, color: DGRAY, fontFace: "Calibri" });
    s.addText(a.note, { x: 6.42, y: y + 0.66, w: 3.2, h: 0.3, fontSize: 8.5, color: "667788", fontFace: "Calibri", italic: true });
  });

  s.addShape(pres.shapes.RECTANGLE, { x: 0.25, y: 3.77, w: 5.8, h: 0.55, fill: { color: "FFF3CD" } });
  s.addText("⚠  CARDINAL RULE: Thiamine → THEN glucose. Never glucose before thiamine in a suspected deficient patient.", {
    x: 0.35, y: 3.79, w: 5.6, h: 0.44,
    fontSize: 10, bold: true, color: RED, fontFace: "Calibri"
  });

  // Electrolytes reminder
  s.addShape(pres.shapes.RECTANGLE, { x: 0.25, y: 4.4, w: 9.5, h: 0.96, fill: { color: LGRAY } });
  s.addText("Electrolyte Correction (Do Not Forget):", {
    x: 0.4, y: 4.44, w: 4, h: 0.28, fontSize: 11, bold: true, color: NAVY, fontFace: "Calibri"
  });
  const electros = [
    "Potassium (K⁺): Hypokalemia (common; lowers seizure threshold) → Oral/IV KCl",
    "Magnesium: Deficiency causes refractory hypokalemia → IV MgSO₄",
    "Glucose: Monitor for hypoglycemia (especially in liver disease)",
    "Sodium: Hyponatremia can mimic/precipitate seizures",
  ];
  electros.forEach((e, i) => {
    s.addText("• " + e, {
      x: 0.4 + (i % 2) * 4.7,
      y: 4.75 + Math.floor(i / 2) * 0.28,
      w: 4.55, h: 0.26,
      fontSize: 9, color: DGRAY, fontFace: "Calibri"
    });
  });
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 10 — DELIRIUM TREMENS
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  const s = pres.addSlide();
  addBg(s, NAVY);
  s.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: 10, h: 0.55, fill: { color: RED } });
  s.addText("⚠  DELIRIUM TREMENS — The Most Dangerous Complication", {
    x: 0.3, y: 0.07, w: 9.4, h: 0.42,
    fontSize: 17, bold: true, color: WHITE, fontFace: "Calibri"
  });

  // Key facts banner
  s.addShape(pres.shapes.RECTANGLE, { x: 0.25, y: 0.68, w: 9.5, h: 0.5, fill: { color: "1A1A2E" } });
  s.addText("Onset: 48-72h after last drink  |  Occurs in ~30% of AWS  |  Untreated mortality: up to 15%  |  Treated mortality: 1-5%", {
    x: 0.35, y: 0.72, w: 9.3, h: 0.38,
    fontSize: 11, color: AMBER, align: "center", fontFace: "Calibri", bold: true
  });

  // Features + Management side by side
  // Features
  s.addShape(pres.shapes.RECTANGLE, { x: 0.25, y: 1.28, w: 4.5, h: 0.36, fill: { color: RED } });
  s.addText("Clinical Features", { x: 0.35, y: 1.3, w: 4.3, h: 0.3, fontSize: 13, bold: true, color: WHITE, fontFace: "Calibri" });
  const features = [
    "Disorientation and confusion",
    "Agitation / combativeness",
    "Fever (>38.5°C)",
    "Profuse diaphoresis",
    "Tachycardia (HR >100)",
    "Hypertension",
    "Vivid visual hallucinations",
    "Autonomic instability",
    "Risk of status epilepticus",
  ];
  features.forEach((f, i) => {
    s.addText([
      { text: "✕  ", options: { color: RED, bold: true } },
      { text: f, options: { color: WHITE } }
    ], { x: 0.35, y: 1.72 + i * 0.37, w: 4.3, h: 0.34, fontSize: 10.5, fontFace: "Calibri" });
  });

  // Management
  s.addShape(pres.shapes.RECTANGLE, { x: 5.0, y: 1.28, w: 4.75, h: 0.36, fill: { color: TEAL } });
  s.addText("Management", { x: 5.1, y: 1.3, w: 4.5, h: 0.3, fontSize: 13, bold: true, color: WHITE, fontFace: "Calibri" });
  const mgmt = [
    ["ICU Admission", "Continuous monitoring essential"],
    ["IV BZD loading", "Diazepam 10mg IV q10min until calm; or lorazepam 2-4mg IV"],
    ["Thiamine IV", "200mg IV BEFORE any glucose — non-negotiable"],
    ["IV Fluids", "Rehydration + electrolyte correction (K⁺, Mg²⁺)"],
    ["Phenobarbital", "BZD-refractory cases — adjunct anticonvulsant"],
    ["Antipsychotics", "Haloperidol for agitation (not for seizures)"],
    ["Airway", "Intubation if repeated IV boluses needed or GCS falls"],
    ["Treat triggers", "Infection, pain, metabolic — common precipitants"],
  ];
  mgmt.forEach((m, i) => {
    s.addText(m[0] + ":", { x: 5.1, y: 1.72 + i * 0.37, w: 1.5, h: 0.34, fontSize: 9.5, bold: true, color: AMBER, fontFace: "Calibri" });
    s.addText(m[1], { x: 6.65, y: 1.72 + i * 0.37, w: 3.0, h: 0.34, fontSize: 9.5, color: WHITE, fontFace: "Calibri" });
  });
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 11 — WERNICKE-KORSAKOFF
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  const s = pres.addSlide();
  addBg(s, WHITE);
  s.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: 10, h: 0.55, fill: { color: "8B4513" } });
  s.addText("Wernicke-Korsakoff Syndrome — Thiamine Deficiency Spectrum", {
    x: 0.3, y: 0.07, w: 9.4, h: 0.42,
    fontSize: 17, bold: true, color: WHITE, fontFace: "Calibri"
  });

  // Two columns: Wernicke | Korsakoff
  const sides = [
    {
      title: "WERNICKE'S ENCEPHALOPATHY",
      subtitle: "Acute — Reversible if treated early",
      color: AMBER,
      items: [
        "Classic triad (present in <20%!):",
        "  → Ophthalmoplegia / Nystagmus",
        "  → Ataxia",
        "  → Confusion / Altered consciousness",
        "",
        "Broader symptoms to watch for:",
        "  → Hypothermia, Hypotension",
        "  → Memory disturbance",
        "  → Peripheral neuropathy",
        "",
        "Treatment: 200-500mg thiamine IV TID x 3 days",
        "Reversible with prompt treatment",
      ]
    },
    {
      title: "KORSAKOFF SYNDROME",
      subtitle: "Chronic — Often irreversible",
      color: RED,
      items: [
        "Develops from untreated Wernicke's",
        "Classic features:",
        "  → Severe anterograde amnesia",
        "  → Retrograde amnesia",
        "  → Confabulation (fabricated memories)",
        "  → Personality change",
        "  → Relatively preserved intelligence",
        "",
        "Damage: mammillary bodies + thalamus",
        "80% have persistent deficits",
        "Prevention is the ONLY effective strategy",
      ]
    }
  ];

  sides.forEach((side, i) => {
    const x = 0.25 + i * 4.9;
    s.addShape(pres.shapes.RECTANGLE, { x, y: 0.65, w: 4.6, h: 4.75, fill: { color: LGRAY } });
    s.addShape(pres.shapes.RECTANGLE, { x, y: 0.65, w: 4.6, h: 0.75, fill: { color: side.color } });
    s.addText(side.title, { x: x + 0.1, y: 0.68, w: 4.4, h: 0.38, fontSize: 12, bold: true, color: WHITE, fontFace: "Calibri" });
    s.addText(side.subtitle, { x: x + 0.1, y: 1.02, w: 4.4, h: 0.3, fontSize: 9.5, color: WHITE, italic: true, fontFace: "Calibri" });
    side.items.forEach((item, j) => {
      if (item === "") return;
      s.addText(item, {
        x: x + 0.12, y: 1.5 + j * 0.32, w: 4.35, h: 0.3,
        fontSize: 10, color: DGRAY, fontFace: "Calibri",
        bold: item.endsWith(":") || item.startsWith("Treatment")
      });
    });
  });

  // Bottom prevention rule
  s.addShape(pres.shapes.RECTANGLE, { x: 0.25, y: 5.22, w: 9.5, h: 0.3, fill: { color: "FFF3CD" } });
  s.addText("Prevention = Prophylactic IV/IM Thiamine in ALL hospitalised alcohol-dependent patients before any glucose administration", {
    x: 0.35, y: 5.24, w: 9.3, h: 0.24,
    fontSize: 9.5, bold: true, color: RED, fontFace: "Calibri"
  });
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 12 — DRUG THERAPY PROBLEMS (Pharmacist Interventions)
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  const s = pres.addSlide();
  addBg(s, WHITE);
  s.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: 10, h: 0.55, fill: { color: NAVY } });
  s.addText("Drug Therapy Problems — Pharmacist Interventions", {
    x: 0.3, y: 0.07, w: 9.4, h: 0.42,
    fontSize: 18, bold: true, color: WHITE, fontFace: "Calibri"
  });

  const dtps = [
    { no: "1", type: "ADR Prevention", prob: "Thiamine–glucose sequencing", action: "Confirm thiamine given BEFORE dextrose; educate nurses on MAR", col: TEAL },
    { no: "2", type: "Needs Drug Therapy", prob: "Hypokalemia untreated (K 3.13)", action: "Recommend KCl supplementation; add MgSO₄ to prevent refractory hypokalemia", col: RED },
    { no: "3", type: "ADR / Monitoring", prob: "Elevated lipase (188 U/L)", action: "Alert physician re: pancreatitis; monitor trend; counsel on alcohol", col: AMBER },
    { no: "4", type: "Dosing / Monitoring", prob: "No CIWA-Ar score documented", action: "Recommend CIWA-Ar q4-8h; adjust BZD dose to objective score", col: "1A5276" },
    { no: "5", type: "Unnecessary Drug?", prob: "Levetiracetam role unclear", action: "Clarify if pre-existing epilepsy separate from AWS; formalize epilepsy plan", col: "6C3483" },
    { no: "6", type: "Route / Omission", prob: "IV PPI not stepped to oral; not on discharge Rx", action: "Step down to oral pantoprazole by Day 2-3; verify discharge omission intentional", col: "117A65" },
  ];

  dtps.forEach((d, i) => {
    const x = 0.18 + (i % 2) * 4.92;
    const y = 0.68 + Math.floor(i / 2) * 1.6;
    s.addShape(pres.shapes.RECTANGLE, {
      x, y, w: 4.7, h: 1.48,
      fill: { color: WHITE },
      shadow: { type: "outer", color: "AAAAAA", blur: 4, offset: 1, angle: 135, opacity: 0.15 }
    });
    s.addShape(pres.shapes.RECTANGLE, { x, y, w: 0.52, h: 1.48, fill: { color: d.col } });
    s.addText(d.no, { x, y: y + 0.48, w: 0.52, h: 0.5, fontSize: 18, bold: true, color: WHITE, align: "center", fontFace: "Calibri" });
    s.addText(d.type, { x: x + 0.6, y: y + 0.08, w: 4.0, h: 0.28, fontSize: 10, bold: true, color: d.col, fontFace: "Calibri" });
    s.addText("Problem: " + d.prob, { x: x + 0.6, y: y + 0.38, w: 4.0, h: 0.38, fontSize: 9.5, color: DGRAY, fontFace: "Calibri" });
    s.addText("Action: " + d.action, { x: x + 0.6, y: y + 0.76, w: 4.0, h: 0.58, fontSize: 9, color: "445566", fontFace: "Calibri", italic: true });
  });
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 13 — DISCHARGE & COUNSELING
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  const s = pres.addSlide();
  addBg(s, WHITE);
  s.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: 10, h: 0.55, fill: { color: TEAL } });
  s.addText("Discharge Medications & Patient Counseling", {
    x: 0.3, y: 0.07, w: 9.4, h: 0.42,
    fontSize: 20, bold: true, color: WHITE, fontFace: "Calibri"
  });

  // Discharge meds table
  s.addText("Discharge Prescription (x14 days)", {
    x: 0.3, y: 0.65, w: 5.5, h: 0.32,
    fontSize: 13, bold: true, color: NAVY, fontFace: "Calibri"
  });
  const meds = [
    ["Drug", "Dose", "Schedule", "Purpose"],
    ["T. Thiamine", "100mg", "1–0–1", "Rebuild B1 stores; prevent WE recurrence"],
    ["T. Diazepam", "5mg", "0–0–2", "Continued gradual detox / nocte seizure prophylaxis"],
    ["T. Sodium Valproate", "200mg", "2–0–2", "Anticonvulsant maintenance (epilepsy + AWS)"],
    ["B-Complex Tablet", "—", "1–0–1", "Replenish B2, B6, B12, folate"],
  ];
  const colW = [1.9, 0.7, 0.8, 2.3];
  const colX = [0.3, 2.22, 2.95, 3.78];
  meds.forEach((row, ri) => {
    const y = 1.02 + ri * 0.45;
    const bg = ri === 0 ? NAVY : ri % 2 === 0 ? LGRAY : WHITE;
    s.addShape(pres.shapes.RECTANGLE, { x: 0.3, y, w: 5.78, h: 0.43, fill: { color: bg } });
    row.forEach((cell, ci) => {
      s.addText(cell, {
        x: colX[ci] + 0.05, y: y + 0.05, w: colW[ci] - 0.1, h: 0.34,
        fontSize: ri === 0 ? 10 : 9.5,
        bold: ri === 0 || ci === 0,
        color: ri === 0 ? WHITE : DGRAY,
        fontFace: "Calibri"
      });
    });
  });

  // Counseling points
  s.addText("Key Patient Counseling Points", {
    x: 6.35, y: 0.65, w: 3.4, h: 0.32,
    fontSize: 13, bold: true, color: NAVY, fontFace: "Calibri"
  });
  const counsel = [
    ["🚫", "No alcohol", "Even one drink can restart the cycle — relapse triggers seizures"],
    ["💊", "Adherence", "Complete full 14-day course; do not stop valproate suddenly"],
    ["🍳", "With food", "Take valproate with meals to reduce nausea"],
    ["⚠", "Diazepam", "Nocte only; no extra doses; extremely dangerous with alcohol"],
    ["🔁", "Follow-up", "Repeat LFTs, serum K, lipase in 2 weeks"],
    ["🏥", "Return if:", "Shaking, confusion, hallucinations, severe abdominal pain"],
    ["🧠", "Referral", "De-addiction psychiatry; structured support program"],
  ];
  counsel.forEach((c, i) => {
    s.addShape(pres.shapes.RECTANGLE, { x: 6.3, y: 1.02 + i * 0.61, w: 3.45, h: 0.55, fill: { color: i % 2 === 0 ? LGRAY : WHITE } });
    s.addText(c[0], { x: 6.33, y: 1.07 + i * 0.61, w: 0.35, h: 0.4, fontSize: 14, align: "center" });
    s.addText(c[1] + ": ", { x: 6.72, y: 1.07 + i * 0.61, w: 0.75, h: 0.2, fontSize: 9, bold: true, color: NAVY, fontFace: "Calibri" });
    s.addText(c[2], { x: 6.72, y: 1.27 + i * 0.61, w: 2.9, h: 0.26, fontSize: 8.5, color: DGRAY, fontFace: "Calibri" });
  });

  // Warning signs row
  s.addShape(pres.shapes.RECTANGLE, { x: 0.3, y: 5.0, w: 9.4, h: 0.5, fill: { color: "FFF3CD" } });
  s.addText("⚠  Warn patient: Stopping alcohol suddenly at home WITHOUT medical supervision is dangerous — advise supervised detox program", {
    x: 0.4, y: 5.03, w: 9.2, h: 0.42,
    fontSize: 10, bold: true, color: RED, fontFace: "Calibri"
  });
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// SLIDE 14 — SUMMARY / KEY TAKEAWAYS
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
{
  const s = pres.addSlide();
  addBg(s, NAVY);
  s.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: 10, h: 0.08, fill: { color: AMBER } });
  s.addShape(pres.shapes.RECTANGLE, { x: 0, y: 5.545, w: 10, h: 0.08, fill: { color: AMBER } });

  s.addText("10 KEY TAKEAWAYS", {
    x: 0.5, y: 0.18, w: 9, h: 0.52,
    fontSize: 28, bold: true, color: WHITE, align: "center", fontFace: "Calibri", charSpacing: 3
  });
  s.addShape(pres.shapes.RECTANGLE, { x: 3.0, y: 0.72, w: 4, h: 0.06, fill: { color: AMBER } });

  const takes = [
    ["01", "AWS seizures peak 12-24h after last drink (up to 48h)"],
    ["02", "Mechanism: GABA-A down-regulation + NMDA up-regulation → hyperexcitability"],
    ["03", "CIWA-Ar score every 4-8h guides benzodiazepine dosing — use it"],
    ["04", "Chlordiazepoxide = gold standard for detox; Lorazepam IV for acute seizures (NNT=5)"],
    ["05", "THIAMINE BEFORE GLUCOSE — non-negotiable rule; prevents Wernicke's"],
    ["06", "Hypokalemia + Hypomagnesemia → lower seizure threshold — correct both"],
    ["07", "Delirium tremens onset 48-72h; mortality up to 15% untreated — escalate early"],
    ["08", "GGT is the most sensitive enzyme marker for chronic alcohol use"],
    ["09", "Pharmacist: identify DTPs (untreated hypokalemia, CIWA-Ar omission, sequencing)"],
    ["10", "Discharge counseling + de-addiction referral = essential to prevent relapse"],
  ];

  takes.forEach((t, i) => {
    const col = i < 5 ? 0 : 1;
    const row = i % 5;
    const x = 0.3 + col * 4.9;
    const y = 0.88 + row * 0.88;
    s.addShape(pres.shapes.RECTANGLE, { x, y, w: 4.6, h: 0.78, fill: { color: "0A2540" } });
    s.addShape(pres.shapes.RECTANGLE, { x, y, w: 0.48, h: 0.78, fill: { color: AMBER } });
    s.addText(t[0], { x, y: y + 0.17, w: 0.48, h: 0.44, fontSize: 14, bold: true, color: NAVY, align: "center", fontFace: "Calibri" });
    s.addText(t[1], { x: x + 0.55, y: y + 0.1, w: 3.97, h: 0.58, fontSize: 10, color: WHITE, fontFace: "Calibri" });
  });
}

// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
// WRITE FILE
// ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
pres.writeFile({ fileName: "/home/daytona/workspace/aws-presentation/Alcohol_Withdrawal_Management.pptx" })
  .then(() => console.log("DONE"))
  .catch(e => { console.error("ERROR", e); process.exit(1); });
Running Command

cd /home/daytona/workspace/aws-presentation && node build.js 2>&1

Running Command

ls -lh /home/daytona/workspace/aws-presentation/Alcohol_Withdrawal_Management.pp…

Your presentation is ready! (410 KB, 14 slides)

Alcohol Withdrawal Management

Presentation · PPTX


Here is what is inside each slide:
#SlideContent
1TitleBold Navy/Teal/Amber design
2Agenda9 topic cards with descriptions
3Section DividerPathophysiology opener
4GABA/NMDA Mechanism3-state flow: Chronic use → Cessation → Clinical result
5Clinical TimelineFlag-post timeline showing 6-8h, 12-24h, 12-36h, 48-72h events
6CIWA-Ar ScoringAll 10 items + 4-tier severity/action table (color-coded)
7Section DividerPharmacotherapy opener
8Benzodiazepines3-column comparison: Chlordiazepoxide / Diazepam / Lorazepam with doses, pros, cautions
9Thiamine & AdjunctsThiamine rules, cardinal warning, electrolytes, valproate, levetiracetam, B-complex
10Delirium TremensFeatures vs. Management side-by-side on dark red background
11Wernicke-KorsakoffTwo-column spectrum: acute vs. chronic, prevention rule
12Drug Therapy Problems6 pharmacist intervention cards (matching this case)
13Discharge & CounselingMedication table + 7 patient counseling points
14Key Takeaways10 numbered cards in gold-on-navy

Teach me this case thoroughly for my presentation teacge me patho of disease treatment guidleine and drugs with there class and moa

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
I have all the evidence needed. Here is the full deep-teach write-up:

🧠 ALCOHOL WITHDRAWAL SYNDROME — Complete Teaching Guide

For Presentation: Pathophysiology + Guidelines + All Drugs with Class & MOA


PART 1: UNDERSTANDING THE DISEASE

1.1 What Is Alcohol Use Disorder (AUD)?

Chronic, compulsive alcohol consumption leads to neuroadaptation - the brain physically rewires itself to function in the constant presence of alcohol. When alcohol is suddenly removed or reduced, this adapted brain is thrown into a hyperexcitable state. That is Alcohol Withdrawal Syndrome (AWS).

1.2 PATHOPHYSIOLOGY — The Core Mechanism

The Two Systems That Alcohol Disrupts

The brain maintains a constant balance between two opposing forces:
SystemReceptorEffectNeurotransmitter
InhibitoryGABA-ACalms the brainγ-Aminobutyric acid (GABA)
ExcitatoryNMDAStimulates the brainGlutamate
Alcohol acts simultaneously on both systems:

Step 1: During Chronic Alcohol Use

Alcohol POTENTIATES GABA-A (mimics GABA):
  • Alcohol binds to GABA-A receptor complex → opens Cl⁻ channel more frequently → hyperpolarizes neuron → inhibition
  • The brain interprets this as "too much inhibition" and compensates:
    • Down-regulates GABA-A receptors (fewer receptors, less sensitive)
Alcohol INHIBITS NMDA receptors (blocks glutamate):
  • Alcohol blocks NMDA receptor → less excitatory drive
  • The brain compensates:
    • Up-regulates NMDA receptors (more receptors, more sensitive)
This is neuroadaptation - the brain has recalibrated to maintain homeostasis in the presence of alcohol.

Step 2: Abrupt Cessation (What Happens in This Patient)

When Mr. S stopped drinking 2 days before admission:
ALCOHOL REMOVED
      ↓
GABA-A inhibition DROPS (down-regulated, fewer receptors)
      +
NMDA excitation UNMASKED (up-regulated, more receptors)
      ↓
NET RESULT: BRAIN IS HYPEREXCITABLE
      ↓
Seizures | Tremors | Hallucinations | Autonomic storm | Delirium Tremens
Mechanistically (from Kaplan & Sadock's):
"Benzodiazepines bind to a distinct site on the GABA-A receptor complex and allosterically increase the frequency of Cl⁻ channel opening in response to GABA. Chronic alcohol exposure leads to alterations of GABAergic neurotransmission, manifested as tolerance, dependence, and withdrawal."
  • Ethanol specifically enhances tonic GABA-activated currents through δ-subunit-containing receptors
  • On withdrawal, loss of this tonic inhibition contributes to the hyperexcitable state

Step 3: The Autonomic Component

The limbic system (locus coeruleus) is also disinhibited:
  • Norepinephrine surge → tachycardia (PR 112 in our patient), hypertension, diaphoresis
  • HPA axis activation → cortisol release → agitation
  • This autonomic storm is what makes AWS life-threatening

1.3 CLINICAL TIMELINE — When Each Feature Appears

Last Drink
    │
    ├── 6-8 hours:    Tremor, anxiety, diaphoresis, nausea (earliest)
    │
    ├── 12-24 hours:  ⚡ SEIZURES (tonic-clonic) — PEAK RISK WINDOW
    │                 Alcoholic hallucinosis begins (visual/tactile)
    │
    ├── 24-48 hours:  Tremulousness peaks; hallucinations continue
    │
    └── 48-72+ hours: 💀 DELIRIUM TREMENS (most dangerous)
                      Confusion, fever, diaphoresis, autonomic instability
Our patient: Last drink = 2 days ago (≈48h). Presented with tonic-clonic seizure + LOC + tongue bite = textbook alcohol withdrawal seizure at peak timing window.
From ROSEN's Emergency Medicine:
"Withdrawal seizures occur 6-48 hours after cessation. 90% have 1-6 generalized tonic-clonic seizures; 60% experience multiple seizures within a 6-hour period."

1.4 WHY DID THIS PATIENT SEIZE? (Compounding Factors)

FactorValue in this PatientEffect on Seizure Risk
Alcohol withdrawal2 days post last drinkPrimary cause ↑↑↑
HypokalemiaK = 3.13 mEq/LLowers seizure threshold ↑
Chronic alcohol x10 yearsSocial historyMore severe neuroadaptation ↑
Prior withdrawal seizure1 year agoStrongest predictor of recurrence ↑↑
Known epilepsyPast historyAdditive risk ↑
Grade II fatty liverUSGImpaired drug metabolism
The "kindling" phenomenon: Each successive withdrawal episode tends to be more severe due to progressive neural sensitization.

1.5 ORGAN DAMAGE FROM CHRONIC ALCOHOLISM (Supported by Labs)

OrganFinding in this PatientMechanism
LiverAST 70, ALT 92, ALP 158, GGT 335Direct hepatotoxicity; oxidative stress via acetaldehyde
PancreasLipase 188 (elevated)Direct toxic effect of alcohol on acinar cells
Bone MarrowPlatelets 93×10³ (low)Direct bone marrow suppression; folate deficiency
BrainAlcohol withdrawal seizuresGABA/NMDA imbalance (see above)
Liver (structural)Grade II fatty liver on USGTriglyceride accumulation (impaired β-oxidation)
GGT 335 is the most diagnostically important enzyme here - GGT is the single most sensitive marker of chronic alcohol use and hepatic microsomal induction.

PART 2: TREATMENT GUIDELINES

2.1 Evidence Base

The management of AWS is guided by:
  • NICE Guidelines (UK) - Alcohol Use Disorders
  • British Association for Psychopharmacology (BAP)
  • SAMHSA (USA) - Alcohol Withdrawal Management
  • Cochrane Systematic Review - Benzodiazepines for AWS (supporting BZD as first-line)

2.2 CIWA-Ar GUIDED TREATMENT FRAMEWORK

From Maudsley Prescribing Guidelines 15e:
CIWA-Ar ScoreSeverityTreatment SettingPharmacotherapy
≤ 8MildHome/outpatientMonitoring only; oral BZD if symptomatic
9-15ModerateCommunity/GPChlordiazepoxide taper; oral thiamine
> 15SevereHospitalIV/IM BZD; IV thiamine; electrolyte correction
>10 + comorbidityComplexHospitalFull regimen; specialist care
This patient = Hospital (Severe/Complex): CIWA likely >15 given seizures + tachycardia + known prior AWS + comorbid epilepsy.

2.3 The 5 Pillars of AWS Management

1. BENZODIAZEPINES ── Treat the neuroadaptation (first-line)
2. THIAMINE IV ────── Prevent Wernicke's Encephalopathy (mandatory)
3. IV FLUIDS ──────── Correct dehydration + electrolytes
4. ANTICONVULSANTS ── For refractory seizures / comorbid epilepsy
5. MONITORING ─────── CIWA-Ar score q4-8h; vitals; LOC

PART 3: ALL DRUGS — CLASS, MOA, DOSE, RATIONALE


DRUG 1: Inj. Thiamine (Vitamin B1)

FieldDetails
ClassWater-soluble vitamin / Nutritional supplement
Dose in case200mg IV OD (inpatient); 100mg oral BD (discharge x14d)

Mechanism of Action

Thiamine (Vitamin B1) is an essential coenzyme in carbohydrate metabolism:
  • Active form: Thiamine pyrophosphate (TPP)
  • Required by: Pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, transketolase
  • These enzymes produce NADH and FADH₂ for the Krebs cycle and the pentose phosphate pathway (critical for neuronal energy supply and myelin synthesis)
In alcoholism: Dual mechanism of depletion:
  1. Poor dietary intake
  2. Impaired intestinal absorption + reduced hepatic storage
Without thiamine: Glucose metabolism stalls → lactate accumulates → neurons in mammillary bodies and thalamus die → Wernicke's Encephalopathy → Korsakoff Syndrome
Why IV? Oral absorption is unreliable in alcoholics (impaired thiamine transporter). IV ensures 100% bioavailability.
The cardinal rule: Thiamine BEFORE glucose. Administering glucose to a thiamine-deficient patient acutely consumes the last reserves of TPP → precipitates acute Wernicke's.

DRUG 2: T. Chlordiazepoxide (Librium)

FieldDetails
ClassBenzodiazepine (long-acting) / CNS depressant
Dose in case10mg TID (2-2-2, Day 1 only with tapering)

Mechanism of Action

Target: GABA-A receptor complex (ligand-gated Cl⁻ ion channel)
  • Chlordiazepoxide binds to the benzodiazepine allosteric site (between α and γ subunits of the GABA-A receptor)
  • This binding does NOT open the channel directly
  • Instead, it increases the FREQUENCY of Cl⁻ channel opening in response to GABA
  • More Cl⁻ enters → greater hyperpolarization → neuronal inhibition
  • Effectively restores the GABA-ergic inhibition that is lost during alcohol withdrawal
From Kaplan & Sadock's:
"Benzodiazepines allosterically increase the frequency of channel opening in response to GABA... they enhance phasic responses to synaptically released GABA."
Why long-acting (t½ ~10-100h + active metabolites)?
  • Provides smooth, self-tapering detoxification
  • Prevents breakthrough seizures between doses
  • Less "peaks and troughs" than short-acting agents
Cross-tolerance with alcohol: Both act at GABA-A → BZDs can "substitute" for alcohol and be gradually withdrawn safely.

DRUG 3: T. Diazepam (Valium)

FieldDetails
ClassBenzodiazepine (long-acting) / CNS depressant
Dose in case5mg nocte OD (discharge x14d)

Mechanism of Action

Identical to chlordiazepoxide — allosteric positive modulator of GABA-A receptor, increasing Cl⁻ channel opening frequency.
Why switched from chlordiazepoxide to diazepam?
  • Diazepam at low nocte dose = step-down maintenance after the acute detox phase
  • 5mg nocte provides ongoing seizure prophylaxis (especially important at night when seizure threshold is lowest)
  • Also has muscle relaxant properties helpful in residual tremors

DRUG 4: Inj. Lorazepam (Ativan)

FieldDetails
ClassBenzodiazepine (short-to-intermediate acting) / CNS depressant
Dose in case2mg IV SOS (acute breakthrough seizures)

Mechanism of Action

Same GABA-A allosteric modulation as above — increases Cl⁻ channel opening FREQUENCY.
Why lorazepam specifically for acute seizures?
  • Only BZD proven in RCTs to reduce seizure recurrence (NNT = 5 to prevent further seizures in the next 6 hours) - ROSEN's Emergency Medicine
  • Safe in liver disease - undergoes direct glucuronidation (not CYP-dependent), so even with AST/ALT elevated, it is metabolized reliably
  • Predictable IM absorption (unlike diazepam which is erratically absorbed IM)
  • Faster onset IV vs. oral BZDs

DRUG 5: Inj. Levetiracetam (Keppra)

FieldDetails
ClassSecond-generation antiepileptic / Synaptic vesicle protein modulator
Dose in case500mg IV BD (removed on Day 4)

Mechanism of Action (unique - unlike all other anticonvulsants)

From Goodman & Gilman's Pharmacological Basis of Therapeutics:
"The synaptic vesicle protein SV2A mediates the anticonvulsant effects of levetiracetam. Binding to SV2A modifies the release of glutamate and GABA through an action on vesicular function."
Multi-pronged mechanism:
  1. SV2A binding → modulates neurotransmitter vesicle exocytosis → reduces glutamate release (less excitation)
  2. Inhibits N-type voltage-gated Ca²⁺ channels → reduces calcium-dependent neurotransmitter release
  3. Inhibits intracellular Ca²⁺ store release → blunts Ca²⁺-mediated neuronal firing
Why added here? This patient had:
  • Comorbid known epilepsy (independent of AWS)
  • High seizure risk (prior AWS seizure + CIWA likely >15)
  • Levetiracetam provides broad anticonvulsant cover with no hepatic enzyme induction (critically important with elevated LFTs)
  • No drug interactions - does not affect CYPs, no interaction with BZDs or valproate
Why removed Day 4? The acute withdrawal window (48h) had passed - lorazepam SOS was sufficient as backup.

DRUG 6: T. Sodium Valproate (SVP)

FieldDetails
ClassBroad-spectrum antiepileptic / Mood stabilizer
Dose in case200mg BD (2-0-2 inpatient; continued at discharge x14d)

Mechanism of Action (multiple, from Stahl's Essential Psychopharmacology)

Valproate acts through at least 3 distinct mechanisms:
  1. Voltage-sensitive sodium channel (VSSC) blockade
    • Inhibits VSSCs → reduces Na⁺ influx → stabilizes neuronal membrane
    • Reduces repetitive high-frequency neuronal firing
    • Possibly by changing phosphorylation of channel subunits
  2. GABA enhancement (multiple pathways)
    • Inhibits GABA-transaminase (GABA-T) → less GABA breakdown → more GABA available
    • Enhances GABA release
    • Inhibits GABA reuptake
    • Net effect: increased inhibitory tone
  3. Indirect glutamate/NMDA blockade
    • Reduced Na⁺-dependent firing → less glutamate excitatory neurotransmission
From Stahl's: "Valproate may work by interfering with voltage-sensitive sodium channels, enhancing inhibitory GABA actions, and regulating downstream signal transduction cascades."
Why used here?
  • Known epilepsy comorbidity → ongoing seizure prophylaxis needed even after AWS resolves
  • Dual action (GABA + Na channel) addresses both the withdrawal component and the underlying epilepsy
  • No dose adjustment needed for moderate liver disease at 200mg BD dose

DRUG 7: Inj. Pantoprazole (Protonix)

FieldDetails
ClassProton Pump Inhibitor (PPI) / Antisecretory agent
Dose in case40mg IV OD

Mechanism of Action

  • Pantoprazole is a prodrug - activated in the acidic pH of the gastric parietal cell's canaliculi
  • Activated form binds irreversibly (covalent disulfide bond) to the H⁺/K⁺ ATPase (the "proton pump") on the apical membrane of gastric parietal cells
  • This pump is the final common pathway of gastric acid secretion
  • Irreversible inhibition → acid suppression for ~24-48h (until new pumps are synthesized)
Why in this patient?
  • Chronic alcohol causes direct gastric mucosal erosions, hyperemia, and impaired mucosal barrier
  • Alcohol stimulates gastric acid secretion
  • Thrombocytopenia (platelets 93×10³) increases GI bleeding risk
  • Vomiting + nausea present → gastroprotection important
  • Standard of care in any alcoholic admitted for acute illness

DRUG 8: Inj. Ondansetron / Emset (Zofran)

FieldDetails
Class5-HT₃ (serotonin type 3) receptor antagonist / Antiemetic
Dose in case8mg IV BD → SOS from Day 4

Mechanism of Action

From Kaplan & Sadock's:
"The 5-HT₃ receptor is a ligand-gated ion channel. Ondansetron is a 5-HT₃ antagonist that is an effective antiemetic."
  • Serotonin (5-HT) is released from enterochromaffin cells in the GI tract during nausea-provoking stimuli
  • 5-HT₃ receptors on vagal afferent neurons → activated → send vomiting signal to the chemoreceptor trigger zone (CTZ) and vomiting center
  • Ondansetron selectively blocks 5-HT₃ receptors peripherally (GI tract) and centrally (CTZ in area postrema)
  • Result: interrupts the vomiting reflex at both ends
Why in this patient?
  • Alcohol withdrawal causes nausea/vomiting (autonomic hyperactivity)
  • Vomiting prevents oral drug absorption (thiamine, BZDs, valproate)
  • Electrolyte losses via vomiting worsen hypokalemia (already low)

DRUG 9: B-Complex Tablets (BCT)

FieldDetails
ClassMulti-vitamin / Nutritional supplement
Dose in case1-0-1 (inpatient + discharge x14d)

Mechanism

Alcoholics are universally deficient in B-vitamins due to:
  • Poor dietary intake
  • Impaired GI absorption
  • Increased urinary excretion
  • Impaired hepatic storage and activation
VitaminFunctionDeficiency Consequence
B1 (Thiamine)Carbohydrate metabolism / Krebs cycleWernicke's Encephalopathy (given separately)
B2 (Riboflavin)FAD coenzyme / electron transportGlossitis, peripheral neuropathy
B3 (Niacin)NAD coenzyme / energy metabolismPellagra (dermatitis, diarrhea, dementia)
B6 (Pyridoxine)GABA synthesis / amino acid metabolismPeripheral neuropathy, seizures
B9 (Folate)DNA synthesis / red cell maturationMegaloblastic anemia (contributes to low platelets)
B12 (Cobalamin)Myelin synthesis / neurological functionSubacute combined degeneration of spinal cord
Note: B6 (pyridoxine) is directly involved in GABA synthesis - deficiency in alcoholics may independently lower the seizure threshold.

DRUG 10: IV Fluids (Normal Saline + DNS)

FluidClassPurpose
0.9% Normal Saline (NS)Isotonic crystalloidVolume repletion; Na+ correction
5% Dextrose Normal Saline (DNS)Hypertonic glucose + electrolyteCaloric substrate; prevent hypoglycemia
Rate: 80ml/hrMaintenance + mild dehydration correction
Important: DNS was given AFTER thiamine to avoid precipitating Wernicke's.

PART 4: DRUG SUMMARY TABLE — Quick Reference for Presentation

#DrugClassMOA SummaryWhy Given
1Thiamine IVVitamin B1Coenzyme for pyruvate/α-KG dehydrogenase; neuronal energyPrevent Wernicke's; treat deficiency
2ChlordiazepoxideBZD (long-acting)↑ GABA-A Cl⁻ channel opening FREQUENCYGold standard AWS detox
3DiazepamBZD (long-acting)↑ GABA-A Cl⁻ channel opening FREQUENCYStep-down detox; nocte seizure prophylaxis
4LorazepamBZD (short-acting)↑ GABA-A Cl⁻ channel opening FREQUENCYAcute seizure control (NNT=5)
5Levetiracetam2nd-gen AED / SV2A modulatorBinds SV2A → ↓ vesicular glutamate release; blocks N-Ca²⁺High seizure risk + comorbid epilepsy
6Sodium ValproateBroad-spectrum AEDVSSC blockade + GABA-T inhibition + ↑ GABAEpilepsy maintenance + AWS seizure prophylaxis
7PantoprazolePPIIrreversible H⁺/K⁺ ATPase blockade in parietal cellGastroprotection; alcohol erosions
8Ondansetron5-HT₃ antagonistBlocks 5-HT₃ at CTZ + vagal afferentsControl nausea/vomiting
9B-ComplexMulti-vitaminRestores coenzyme activity (FAD, NAD, PLP, TPP)Nutritional repletion; neuroprotection
10IV Fluids (NS/DNS)CrystalloidVolume, electrolyte, glucose replacementDehydration; prevent hypoglycemia

PART 5: KEY PHARMACOLOGICAL CONCEPT — BZD Receptor Comparison

DrugDurationMechanism at GABA-AClinical Use
ChlordiazepoxideVery long (t½ 10-100h)↑ Cl⁻ channel FREQUENCYDetox protocol
DiazepamLong (t½ 20-100h)↑ Cl⁻ channel FREQUENCYAcute seizure + step-down
LorazepamIntermediate (t½ 10-20h)↑ Cl⁻ channel FREQUENCYActive seizure (SOS)
PhenobarbitalLong (t½ 80-120h)↑ Cl⁻ channel DURATIONBZD-refractory AWS
Memory aid:
  • Benzodiazepines → frequency of Cl⁻ channel opening
  • Barbiturates → duration of Cl⁻ channel opening
  • Both → more Cl⁻ → hyperpolarization → inhibition
  • Barbiturates can open the channel WITHOUT GABA (hence more dangerous in overdose)

Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics; Stahl's Essential Psychopharmacology; Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Maudsley Prescribing Guidelines, 15th ed.; ROSEN's Emergency Medicine; Goldman-Cecil Medicine
This is a shared conversation. Sign in to Orris to start your own chat.